Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Making sense of associations between type 2 diabetes, metformin, and breast cancer risk

Abstract

The relationship between type 2 diabetes (T2D), metformin, and breast cancer is complex. T2D may increase risk, but metformin used as first-line treatment of T2D may decrease breast cancer risk. This comment explores efforts to disentangle effects of T2D and metformin use on breast cancer risk in a prospective study.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W. et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 138, 271–281 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3322/caac.21660 (2021).

  3. 3.

    Kang, C., LeRoith, D. & Gallagher, E. J. Diabetes, obesity, and breast cancer. Endocrinology 159, 3801–3812 (2018).

    CAS  Article  Google Scholar 

  4. 4.

    Boyle, P., Boniol, M., Koechlin, A., Robertson, C., Valentini, F., Coppens, K. et al. Diabetes and breast cancer risk: a meta-analysis. Br. J. Cancer 107, 1608–1617 (2012).

    CAS  Article  Google Scholar 

  5. 5.

    Chlebowski, R. T., McTiernan, A., Wactawski-Wende, J., Manson, J. E., Aragaki, A. K., Rohan, T. et al. Diabetes, metformin, and breast cancer in postmenopausal women. J. Clin. Oncol. 30, 2844–2852 (2012).

    Article  Google Scholar 

  6. 6.

    Sanderson, M., Lipworth, L., Shrubsole, M. J., Andersen, S. W., Shu, X. O., Zheng, W. et al. Diabetes, obesity, and subsequent risk of postmenopausal breast cancer among white and black women in the Southern Community Cohort Study. Cancer Causes Control 30, 425–433 (2019).

    Article  Google Scholar 

  7. 7.

    Goodwin, P. J., Ligibel, J. A. & Stambolic, V. Metformin in breast cancer: time for action. J. Clinical oncol. 27, 3271–3273 (2009).

    CAS  Article  Google Scholar 

  8. 8.

    Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. & Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269–10273 (2006).

    CAS  Article  Google Scholar 

  9. 9.

    Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schunemann, H. J. et al. Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a grade-assessed systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 27, 627–635 (2018).

    CAS  Article  Google Scholar 

  10. 10.

    Park, Y. M., Bookwalter, D. B., O’Brien, K. M., Jackson, C. L., Weinberg, C. R. & Sandler, D. P. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann. Oncol. 32, 351–359 (2021).

    Article  Google Scholar 

  11. 11.

    Sandler, D. P., Hodgson, M. E., Deming-Halverson, S. L., Juras, P. S., D’Aloisio, A. A., Suarez, L. M. et al. The Sister Study Cohort: baseline methods and participant characteristics. Environ. Health Perspect. 125, 127003 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

None.

Author information

Affiliations

Authors

Contributions

D.P.S was invited to write this piece by the British Journal of Cancer. Y.-M.M.P. and D.P.S. contributed equally to the writing of the Comment.

Corresponding author

Correspondence to Dale P. Sandler.

Ethics declarations

Ethics approval and consent to participate

Not applicable. This comment includes published findings from the Sister Study. The Sister Study has been approved by the Institutional Review Board of the NIH. All participants provided written informed consent.

Consent to publish

Not applicable.

Data availability

Data from the Sister Study may be requested following procedures outlined at https://sisterstudy.niehs.nih.gov/English/coll-data.htm.

Competing interests

The authors declare no competing interests.

Funding

This work was supported by the Intramural Research Program of the NIH, the National Institute of Environmental Health Sciences (Z01-ES044005 to DPS).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Park, YM.M., Sandler, D.P. Making sense of associations between type 2 diabetes, metformin, and breast cancer risk. Br J Cancer (2021). https://doi.org/10.1038/s41416-021-01372-3

Download citation

Search

Quick links